Welcome to our dedicated page for Emergent Biosolutions news (Ticker: EBS), a resource for investors and traders seeking the latest updates and insights on Emergent Biosolutions stock.
Emergent BioSolutions, Inc. (NYSE: EBS) is a global life sciences company dedicated to protecting and enhancing life. With a mission to secure public health, Emergent develops, manufactures, and distributes a broad portfolio of medical countermeasures for biological and chemical threats as well as emerging infectious diseases. The company is committed to safeguarding lives and aims to protect and enhance 50 million lives with its products by 2025.
Headquartered in Gaithersburg, Maryland, Emergent operates through three primary segments: Commercial, Products, and Services. The Commercial segment, which generates the majority of the company's revenue, includes key products such as NARCAN® Nasal Spray—a life-saving medication for opioid overdoses. NARCAN® has become widely accessible in pharmacies, grocery stores, and online retailers, significantly increasing public availability since its over-the-counter approval by the FDA in March 2023.
Emergent is also known for its role in developing and manufacturing vaccines and therapeutics, particularly for governments and healthcare providers. The company's Baltimore Bayview manufacturing facility recently received a “No Action Indicated” status from the FDA, confirming its compliance with good manufacturing practices. This recognition underscores Emergent's dedication to quality and compliance in its manufacturing processes.
Financially, Emergent is focused on stabilizing its operations and strengthening its balance sheet. The recent restructuring plan aims to streamline operations, close certain manufacturing facilities, and reduce workforce by 300 employees, resulting in annualized savings of approximately $80 million. Despite these changes, Emergent remains dedicated to its core business areas and continues to offer integrated contract development and manufacturing services to pharmaceutical and biotechnology customers.
Key recent developments include the extension of NARCAN® Nasal Spray's shelf life from 36 to 48 months and its widespread distribution across the U.S. and Canada. Emergent is also actively working with partners like the National Safety Council to educate businesses and the public about opioid overdose prevention and response.
Emergent is committed to its long-term vision of protecting and enhancing 1 billion lives by 2030. The company continues to innovate and expand its product offerings while maintaining a strong focus on public health and safety.
Emergent BioSolutions (NYSE: EBS) reported Q2 2022 results with total revenues of $242.7 million, down 39% year-over-year. Net loss reached $56.4 million, marking a significant decline from the prior year's profit of $4.6 million. Adjusted EBITDA stood at $(28.8) million, down from $49.5 million. The company executed an agreement to acquire TEMBEXA and announced an FDA review of its anthrax vaccine. For 2022, total revenue guidance has been set at $1.15 to $1.25 billion, with CDMO revenues projected at $105 to $125 million.
Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on August 1, 2022, at 5:00 PM ET to discuss its Q2 2022 financial results and provide revenue guidance for Q3 2022 and the full year. The call will cover recent business developments and financial outlook. Participants can join via webcast or telephone after registration. A replay will be available on Emergent's Investors page.
Emergent focuses on public health threats, developing vaccines and therapeutics, and offering contract development services.
Emergent BioSolutions (NYSE: EBS) has formed a collaboration with Ridgeback Biotherapeutics to enhance availability of Ebanga™ (Ansuvimab-zykl) for Ebola treatment. Emergent will manage manufacturing, sales, and distribution in the U.S. and Canada, while Ridgeback will ensure free access to patients in endemic regions through its compassionate use program. Ebanga™, FDA-approved since December 2020, is crucial for combating Ebola. The partnership emphasizes both companies' commitment to addressing public health threats and ensuring equitable access to life-saving treatments.
Emergent BioSolutions (NYSE:EBS) appointed Sujata Dayal as a Class II director, effective July 15, 2022, with her term expiring at the 2023 annual meeting. Dayal brings extensive experience in healthcare compliance, having previously served at Medline, Johnson & Johnson, Biomet, and Abbott Laboratories. As a new board member, she joins the Nominating and Corporate Governance Committee and the Special Committee on Manufacturing and Quality Oversight, positioning her to significantly contribute to the company's growth and compliance efforts.
Emergent BioSolutions Inc. (NYSE:EBS) announced that the FDA has accepted for review its Biologics License Application (BLA) for AV7909, a new anthrax vaccine candidate for post-exposure prophylaxis in individuals aged 18-65. The Prescription Drug User Fee Act goal date for the FDA's decision is April 2023. This application is based on pivotal phase 3 clinical study data evaluating the vaccine's efficacy and safety. Emergent has collaborated with the U.S. government for over 20 years on this project, aiming to enhance public health preparedness against anthrax threats.
Emergent BioSolutions (NYSE:EBS) announced the publication of two-year persistence data from its Phase 2 trial of a chikungunya virus vaccine in The Lancet Infectious Diseases. The study involved 415 participants and demonstrated that a single 40 μg dose of the aluminum hydroxide-adjuvanted CHIKV VLP vaccine candidate was well-tolerated, inducing a robust immune response lasting up to two years. The company is moving forward with Phase 3 trials, emphasizing the vaccine's potential to address a public health threat with no existing vaccine or treatment.
Emergent BioSolutions will participate in key investor conferences in June 2022, including:
- Benchmark Healthcare House Call Virtual 1X1 Conference on June 2.
- NYSE Healthcare & Technology Virtual Investor Access Day on June 8.
- East Coast IDEAS Conference on June 22, featuring a pre-recorded presentation accessible at 6:00 am ET.
Webcast presentations may discuss business developments and financial results, available live and on replay via the Emergent website.
Emergent BioSolutions (EBS) has announced its acquisition of TEMBEXA® from Chimerix for $225 million, enhancing its medical countermeasures portfolio against smallpox. The deal is expected to be accretive and funded by current resources, with deliveries to the U.S. government anticipated in 2022. TEMBEXA, the first FDA-approved antiviral for smallpox, is critical for public health preparedness. The transaction also includes potential milestone payments of up to $100 million and royalties based on future procurement.
Emergent BioSolutions Inc. (NYSE: EBS) announced its 2022 Annual Meeting of Stockholders will be held virtually on May 26, 2022, at 9:00 AM EDT. Stockholders of record can participate via live audio webcast, accessing the meeting through a designated website using their unique Control Number. Those without a Control Number can attend in listen-only mode. Full instructions for participation and ownership verification are available online. A replay of the meeting will also be accessible on the Emergent website.
Emergent BioSolutions (EBS) reported Q1 2022 revenues of $307.5M, down 10% from Q1 2021. Adjusted EBITDA decreased 71% to $36M, while net loss reached $3.7M. Key revenue drivers included $103.6M from anthrax vaccines (up 88%) and $93.1M from nasal naloxone products (up 25%). However, contract development manufacturing (CDMO) revenues fell 67% to $60.8M. The company has suspended CDMO guidance due to uncertainties regarding COVID-19 vaccine requirements. EBS reiterated its 2022 revenue guidance for anthrax vaccines and other products.
FAQ
What is the current stock price of Emergent Biosolutions (EBS)?
What is the market cap of Emergent Biosolutions (EBS)?
What is Emergent BioSolutions' core mission?
What are the main segments of Emergent BioSolutions?
What is NARCAN® Nasal Spray?
What recent compliance certification did Emergent receive?
What are Emergent's recent restructuring plans?
How is Emergent enhancing the availability of NARCAN® Nasal Spray?
What financial goals does Emergent have?
What is Emergent's vision for the future?
What services does Emergent offer to pharmaceutical and biotechnology customers?
How can stakeholders participate in Emergent's conference calls?
